Randomized, Open Label, Multicenter Phase IIIb Study Evaluating the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant (Response 2)

Trial Profile

Randomized, Open Label, Multicenter Phase IIIb Study Evaluating the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant (Response 2)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Polycythaemia vera
  • Focus Therapeutic Use
  • Acronyms RESPONSE-2
  • Sponsors Novartis
  • Most Recent Events

    • 25 Jun 2017 Results of a preplanned analysis evaluating the durability of efficacy and safety of ruxolitinib vs Best Available Therapy over 80-weeks of the study, spresented at the 22nd Congress of the European Haematology Association.
    • 18 May 2017 According to a Novartis media release, data from this study will be presented at 22nd Annual Congress of the European Hematology Association (EHA).
    • 07 Mar 2017 Planned End Date changed from 1 Apr 2020 to 20 Apr 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top